RxDoctor Payments Data

Leslie Suranyi, MD

Neurology · Laconia, NHNPI 1942227988

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,571 of the $1,865 with a category attached, or 84.2%. 9 manufacturers reported payments, led by AbbVie at 50.6% of the total.

$1,865in general payments, 2019–2025

Across 79 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Teva Pharmaceuticals USA, Inc.$604
  • EMD Serono, Inc.$100
  • Lilly USA, LLC$77
  • Acadia Pharmaceuticals Inc$39
  • Kyowa Kirin, Inc.$34
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$1,57184%
  • Education$29416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,865 in reported general payments places this provider in the 75th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$107,203
Medicare patients
571
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate42$237,353
GlatopaGlatiramer Acetate21$70,215
FingolimodFingolimod Hcl22$66,903
Nurtec OdtRimegepant Sulfate35$49,194
Aimovig AutoinjectorErenumab-Aooe39$27,876
QuliptaAtogepant23$24,856
OnfiClobazam11$20,256
Emgality PenGalcanezumab-Gnlm27$19,039
VimpatLacosamide13$17,594
Ajovy SyringeFremanezumab-Vfrm17$12,358
Tegretol XrCarbamazepine22$10,817
Rivastigmine52$8,668
Memantine Hcl196$8,019
Levetiracetam189$7,551
Ropinirole Hcl150$6,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$39$237,35342 claims
PfizerNurtec Odt, Dilantin$18$51,92246 claims
AbbVieQulipta$944$24,85623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 neurology providers in New Hampshire.

Other neurology in Laconia

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →